000			02317 a2200673 4500
005			20250516013211.0
264		0	_c20110307
008			201103s 0 0 eng d
022			_a1873-2623
024	7		_a10.1016/j.transproceed.2010.08.045 _2doi
040			_aNLM _beng _cNLM
100	1		_aCiancio, G
245	0	0	_aRandomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. _h[electronic resource]
260			_bTransplantation proceedings _cNov 2010
300			_a3503-6 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAlemtuzumab
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibodies, Neoplasm _xadministration & dosage
650	0	4	_aAntilymphocyte Serum
650	0	4	_aBiomarkers _xblood
650	0	4	_aBiopsy
650	0	4	_aChi-Square Distribution
650	0	4	_aCreatinine _xblood
650	0	4	_aDaclizumab
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aFlorida
650	0	4	_aGraft Rejection _ximmunology
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xadministration & dosage
650	0	4	_aImmunosuppressive Agents _xadministration & dosage
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aKidney Function Tests
650	0	4	_aKidney Transplantation _xadverse effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMycophenolic Acid _xadministration & dosage
650	0	4	_aProspective Studies
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aSteroids _xadministration & dosage
650	0	4	_aTacrolimus _xadministration & dosage
650	0	4	_aTime Factors
650	0	4	_aTransplantation, Homologous
650	0	4	_aTreatment Outcome
700	1		_aGaynor, J J
700	1		_aRoth, D
700	1		_aKupin, W
700	1		_aHanson, L
700	1		_aTueros, L
700	1		_aZarak, A
700	1		_aRuiz, P
700	1		_aBurke, G W
773	0		_tTransplantation proceedings _gvol. 42 _gno. 9 _gp. 3503-6
856	4	0	_uhttps://doi.org/10.1016/j.transproceed.2010.08.045 _zAvailable from publisher's website
999			_c20390984 _d20390984